相关实验视频

Updated: May 11, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

在设计的TGFβRI/TGFβRII受体复杂抑制剂中,表现出体外生物活性

Jacek Plichta¹, Michał Karbownik², Piotr Kuna¹

¹Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland.

Journal of cellular and molecular medicine

|April 17, 2025

概括

针对TGF-β信号通路的新型抑制剂显示出治疗纤维性疾病和癌症的前景. 这些TGF-β抑制剂在没有细胞毒性的情况下表现出显著的体外活性,这需要进一步调查.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

转化生长因子β (TGF-β) 是一个关键的细胞因子,调节细胞过程,如增殖,伤口愈合和免疫反应.
TGF-β信号通路的过活性与各种人类疾病有关,包括纤维性疾病,炎症状况和癌症.
开发针对TGF-β通路的向抑制剂,特别是TGFβ/TGFβRI/TGFβRII复合体,是一个重要的治疗目标.

研究的目的:

设计和评估针对TGFβ/TGFβRI/TGFβRII复合体的新型抑制剂 (PI).
评估这些在设计的PI中的生物活性和细胞毒性.
探索这些PI在与TGF-β通路失调相关的条件中的治疗潜力.

主要方法:

针对TGFβ/TGFβRI/TGFβRII复合体的抑制剂 (PI) 的设计.
在HEK293T细胞中进行基于露西法酶的发光测定,以测量PI活性和确定IC50值.
流细胞计测试以评估PI细胞毒性对HEK293T细胞.

主要成果:

设计的抑制剂在基于细胞的测试中显著降低了发光水平,表明TGF-β通路的抑制.
三个试验剂的疗效与已知小分子TGF-β抑制剂SD-208的疗效相当.
在任何测试的PI中都没有观察到显著的细胞毒性,这表明了有利的安全性.

结论:

这种新型,在中设计的抑制剂在体外表现出强烈的活性,对抗TGF-β信号通路,而不会诱导细胞毒性.
这些PI代表了一种有前途的新疗法类别,用于纤维性疾病,慢性炎症疾病和某些瘤癌症.
计划对癌细胞系和T细胞进行进一步的in silico精炼和体外试验,以推进其发展.

关键词:

在TGF-ββ.纤维化纤维化免疫瘤学免疫瘤学免疫疗法免疫疗法在的中.这是一种抑制剂.瘤微环境是一个微环境.

更多相关视频

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...